| Dr Wei Wei Ma, MD | |
|
65 James St, Edison, NJ 08820-3947 | |
| (732) 321-7010 | |
| (732) 632-1584 |
| Full Name | Dr Wei Wei Ma |
|---|---|
| Gender | Female |
| Speciality | Neurology |
| Experience | 41 Years |
| Location | 65 James St, Edison, New Jersey |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1063412310 | NPI | - | NPPES |
| 0004120 | Medicaid | NJ |
| Facility Name | Location | Facility Type |
|---|---|---|
| Jfk Medical Center | Edison, NJ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Hackensack Meridian Health Medical Group - Specialty Care Pc | 9133032519 | 1090 |
News Archive
Two medications approved as treatment for drug-resistant chronic myeloid leukemia continue to provide patients with quicker, better responses as a first treatment than the existing front-line drug, researchers at The University of Texas M. D. Anderson Cancer Center reported at the 51st Annual Meeting of the American Society of Hematology.
A $500,000 drug development grant from the National Multiple Sclerosis Society was awarded to a partnership between a multiple sclerosis research team at the Icahn School of Medicine at Mount Sinai and Karyopharm Therapeutics Inc., a clinical stage pharmaceutical company. Dr. Patrizia Casaccia, MD, PhD, Professor in the Departments of Neuroscience and Genetics and Genomics, at Icahn School of Medicine at Mount Sinai, will be the academic lead.
EpiCept Corporation announced today that it has entered into a definitive agreement with a single life science focused institutional investor for the purchase of 1,065 shares of its new Series B 0% Convertible Preferred Stock at $1,000 per share, which are convertible into an aggregate of approximately 6.3 million shares of its common stock, and five-year warrants to purchase up to approximately 3.1 million shares of its common stock at an exercise price of $0.17 per share that are immediately exercisable.
Atherosclerosis is a disease in which arteries narrow due to plaques. That narrowing can lead to heart attacks and strokes - both of which are leading causes of death in the U.S.
› Verified 8 days ago
| Entity Name | Hackensack Meridian Health Medical Group - Specialty Care Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1215989249 PECOS PAC ID: 9133032519 Enrollment ID: O20031111000524 |
News Archive
Two medications approved as treatment for drug-resistant chronic myeloid leukemia continue to provide patients with quicker, better responses as a first treatment than the existing front-line drug, researchers at The University of Texas M. D. Anderson Cancer Center reported at the 51st Annual Meeting of the American Society of Hematology.
A $500,000 drug development grant from the National Multiple Sclerosis Society was awarded to a partnership between a multiple sclerosis research team at the Icahn School of Medicine at Mount Sinai and Karyopharm Therapeutics Inc., a clinical stage pharmaceutical company. Dr. Patrizia Casaccia, MD, PhD, Professor in the Departments of Neuroscience and Genetics and Genomics, at Icahn School of Medicine at Mount Sinai, will be the academic lead.
EpiCept Corporation announced today that it has entered into a definitive agreement with a single life science focused institutional investor for the purchase of 1,065 shares of its new Series B 0% Convertible Preferred Stock at $1,000 per share, which are convertible into an aggregate of approximately 6.3 million shares of its common stock, and five-year warrants to purchase up to approximately 3.1 million shares of its common stock at an exercise price of $0.17 per share that are immediately exercisable.
Atherosclerosis is a disease in which arteries narrow due to plaques. That narrowing can lead to heart attacks and strokes - both of which are leading causes of death in the U.S.
› Verified 8 days ago
| Entity Name | Community Hospital Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1225251754 PECOS PAC ID: 3971415209 Enrollment ID: O20031120000589 |
News Archive
Two medications approved as treatment for drug-resistant chronic myeloid leukemia continue to provide patients with quicker, better responses as a first treatment than the existing front-line drug, researchers at The University of Texas M. D. Anderson Cancer Center reported at the 51st Annual Meeting of the American Society of Hematology.
A $500,000 drug development grant from the National Multiple Sclerosis Society was awarded to a partnership between a multiple sclerosis research team at the Icahn School of Medicine at Mount Sinai and Karyopharm Therapeutics Inc., a clinical stage pharmaceutical company. Dr. Patrizia Casaccia, MD, PhD, Professor in the Departments of Neuroscience and Genetics and Genomics, at Icahn School of Medicine at Mount Sinai, will be the academic lead.
EpiCept Corporation announced today that it has entered into a definitive agreement with a single life science focused institutional investor for the purchase of 1,065 shares of its new Series B 0% Convertible Preferred Stock at $1,000 per share, which are convertible into an aggregate of approximately 6.3 million shares of its common stock, and five-year warrants to purchase up to approximately 3.1 million shares of its common stock at an exercise price of $0.17 per share that are immediately exercisable.
Atherosclerosis is a disease in which arteries narrow due to plaques. That narrowing can lead to heart attacks and strokes - both of which are leading causes of death in the U.S.
› Verified 8 days ago
| Entity Name | Hmh Hospitals Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1356016661 PECOS PAC ID: 9032181847 Enrollment ID: O20220304001385 |
News Archive
Two medications approved as treatment for drug-resistant chronic myeloid leukemia continue to provide patients with quicker, better responses as a first treatment than the existing front-line drug, researchers at The University of Texas M. D. Anderson Cancer Center reported at the 51st Annual Meeting of the American Society of Hematology.
A $500,000 drug development grant from the National Multiple Sclerosis Society was awarded to a partnership between a multiple sclerosis research team at the Icahn School of Medicine at Mount Sinai and Karyopharm Therapeutics Inc., a clinical stage pharmaceutical company. Dr. Patrizia Casaccia, MD, PhD, Professor in the Departments of Neuroscience and Genetics and Genomics, at Icahn School of Medicine at Mount Sinai, will be the academic lead.
EpiCept Corporation announced today that it has entered into a definitive agreement with a single life science focused institutional investor for the purchase of 1,065 shares of its new Series B 0% Convertible Preferred Stock at $1,000 per share, which are convertible into an aggregate of approximately 6.3 million shares of its common stock, and five-year warrants to purchase up to approximately 3.1 million shares of its common stock at an exercise price of $0.17 per share that are immediately exercisable.
Atherosclerosis is a disease in which arteries narrow due to plaques. That narrowing can lead to heart attacks and strokes - both of which are leading causes of death in the U.S.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Wei Wei Ma, MD 65 James St, Edison, NJ 08820-3947 Ph: (732) 321-7010 | Dr Wei Wei Ma, MD 65 James St, Edison, NJ 08820-3947 Ph: (732) 321-7010 |
News Archive
Two medications approved as treatment for drug-resistant chronic myeloid leukemia continue to provide patients with quicker, better responses as a first treatment than the existing front-line drug, researchers at The University of Texas M. D. Anderson Cancer Center reported at the 51st Annual Meeting of the American Society of Hematology.
A $500,000 drug development grant from the National Multiple Sclerosis Society was awarded to a partnership between a multiple sclerosis research team at the Icahn School of Medicine at Mount Sinai and Karyopharm Therapeutics Inc., a clinical stage pharmaceutical company. Dr. Patrizia Casaccia, MD, PhD, Professor in the Departments of Neuroscience and Genetics and Genomics, at Icahn School of Medicine at Mount Sinai, will be the academic lead.
EpiCept Corporation announced today that it has entered into a definitive agreement with a single life science focused institutional investor for the purchase of 1,065 shares of its new Series B 0% Convertible Preferred Stock at $1,000 per share, which are convertible into an aggregate of approximately 6.3 million shares of its common stock, and five-year warrants to purchase up to approximately 3.1 million shares of its common stock at an exercise price of $0.17 per share that are immediately exercisable.
Atherosclerosis is a disease in which arteries narrow due to plaques. That narrowing can lead to heart attacks and strokes - both of which are leading causes of death in the U.S.
› Verified 8 days ago
Riffat Sajjad, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 4 Louis Ct, Edison, NJ 08820 Phone: 908-668-7329 | |
Joseph C. Landolfi, DO Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 65 James St, Edison, NJ 08820 Phone: 732-321-7010 Fax: 732-632-1584 | |
Dr. Emad Roshdy Noor, Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 65 James St, Edison, NJ 08820 Phone: 732-321-7010 Fax: 732-744-5873 | |
Phillip D. Kramer, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 65 James St, Edison, NJ 08820 Phone: 732-321-7010 Fax: 732-632-1584 | |
Sudhansu Chokroverty, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 65 James St, Edison, NJ 08820 Phone: 732-321-7010 Fax: 732-632-1584 | |
Niveditha Meghadri, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 295 Pierson Ave, Edison, NJ 08837 Phone: 732-494-8558 |